The latest price target for Day One Biopharmaceutical (NASDAQ:DAWN) was reported by Goldman Sachs on February 10, 2025. The analyst firm set a price target for $43.00 expecting DAWN to rise to within 12 months (a possible 231.69% upside). 26 analyst firms have reported ratings in the last year.

The latest analyst rating for Day One Biopharmaceutical (NASDAQ:DAWN) was provided by Goldman Sachs, and Day One Biopharmaceutical maintained their buy rating.

The last upgrade for Day One Biopharmaceuticals Inc happened on August 1, 2024 when B of A Securities raised their price target to $24. B of A Securities previously had an underperform for Day One Biopharmaceuticals Inc.

The last downgrade for Day One Biopharmaceuticals Inc happened on April 25, 2023 when B of A Securities changed their price target from $34 to $9 for Day One Biopharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Day One Biopharmaceutical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Day One Biopharmaceutical was filed on February 10, 2025 so you should expect the next rating to be made available sometime around February 10, 2026.

While ratings are subjective and will change, the latest Day One Biopharmaceutical (DAWN) rating was a maintained with a price target of $48.00 to $43.00. The current price Day One Biopharmaceutical (DAWN) is trading at is $12.96, which is out of the analyst’s predicted range.